Latest Ibritumomab tiuxetan Stories
SAN DIEGO, Sept. 2 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. , a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced the appointment of Patrick O'Connor, PhD, Vice President, Research, Michael J.
SOUTH SAN FRANCISCO, Calif., Aug. 21 /PRNewswire-FirstCall/ -- Monogram Biosciences, Inc. announced today that Christine A. White, M.D. has been appointed to the company's board of directors.
SEATTLE, Aug. 5 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (the "Company") (Nasdaq: CTIC; MTA) t announced that Craig W. Philips has assumed his role as CTI's new President, and will concentrate on managing the company's drug development and commercial operations.
THE TOBACCO plant - responsible for millions of cancer cases - may actually offer the means to treat one form of the disease, a study says. US scientists used the plant to "grow" key components of a cancer vaccine.
SEATTLE, July 22 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that the Company has scheduled a meeting with the U.S.
Biovest, a subsidiary of Accentia, has announced positive data from a pivotal trial of BiovaxID in lymphoma, and the vaccine now stands a good chance of becoming the first therapeutic cancer vaccine to gain approval in the seven major markets.
SEATTLE, July 15 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc.
By Wahl, Richard L Many of us remember the 1989 film Field of Dreams, starring Kevin Costner. In brief, the main character becomes convinced that a baseball field must be built on his failing farmland. Another character assures him that if he builds it, "they" will come.
SEATTLE, June 20 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC; MTA) held a Special Meeting in lieu of the Annual Meeting of Shareholders on Thursday, June 19, 2008 at its headquarters in Seattle.
Cell Therapeutics has signed an agreement with Bayer Schering Pharma to gain access to Bayer's Phase III Zevalin first-line Indolent trial data.
- In medieval musical notation, a sign or neume denoting a shake or trill.